Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Screening Asia

Mark Frattini's Biography

Mark Frattini, Associate Professor, Columbia University Medical Center

Dr. Mark Frattini serves as Associate Professor of Medicine and Experimental Therapeutics and Director of Research for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Previously, he was a member of the Leukemia Service and Experimental Therapeutics Center at Memorial Sloan-Kettering for nearly 11 years. Dr. Frattini specializes in the treatment of adult patients with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative disorders. His widely published research focuses on developing new treatments for acute and chronic leukemias with a special interest in small molecule inhibitors of cell cycle regulated kinases as therapeutic targets. He has discovered an enzyme inhibitor that is presently in clinical development for Phase I studies in patients with relapsed and/or chemotherapy-refractory disease. His research is also aimed at developing a more personalized approach to determine the best possible response to chemotherapeutic agents for patients with these malignant diseases. Dr. Frattini received his M.D. and Ph.D. in biochemistry and molecular biology from The University of Chicago Pritzker School of Medicine. He completed his internal medicine internship, residency, and medical oncology fellowship training at The Johns Hopkins Hospital.

Mark Frattini Image

Natural Product Drug Discovery for Cancer: From Primary HTS Directly to Phase I Clinical Trial

Wednesday, 13 November 2013 at 16:15

Add to Calendar ▼2013-11-13 16:15:002013-11-13 17:15:00Europe/LondonNatural Product Drug Discovery for Cancer: From Primary HTS Directly to Phase I Clinical TrialScreening Asia in

Natural products have been and continue to be an important source of therapeutic compounds for cancer therapy. I will present data describing identification of a natural product allosteric inhibitor of the human Cdc7 kinase, a heterodimeric serine/threonine kinase and an emerging target for cancer therapy. Importantly, this natural product was identified through HTS and is being taken directly to a Phase I clinical trial.

Add to Calendar ▼2013-11-12 00:00:002013-11-13 00:00:00Europe/LondonScreening AsiaScreening Asia in